Pfizer Names Andrew Baum Chief Strategy, Innovation Officer

By Colin Kellaher

Pfizer had hired Andrew Baum as the drugmaker's next chief strategy and innovation officer.

Pfizer on Monday said Baum, who has been Citi's head of global healthcare and managing director of equity research, joins the New York company as an executive vice president and a member of its executive leadership team, reporting to chairman and chief executive Albert Bourla.

Baum succeeds Aamir Malik, who recently became executive vice president and chief U.S. commercial officer.

Pfizer said Baum, who takes up his new post on June 3, will be responsible for portfolio analysis and prioritization functions and also will serve as chairman of its portfolio-management team, the company's most senior governing body responsible for portfolio management and capital deployment across its research-and-development pipeline.

Baum, who joined Citi in 2011 after covering European pharmaceuticals at Morgan Stanley for 14 years, was a practicing physician earlier in his career, Pfizer said.

Write to Colin Kellaher at colin.kellaher@wsj.com